191 related articles for article (PubMed ID: 37606037)
21. Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma.
Clay MR; Pinto EM; Fishbein L; Else T; Kiseljak-Vassiliades K
J Clin Endocrinol Metab; 2022 Mar; 107(4):1159-1169. PubMed ID: 34850906
[TBL] [Abstract][Full Text] [Related]
22. Squamous cell carcinoma-related oncogene is highly expressed in developing, normal, and adenomatous adrenal tissue but not in aggressive adrenocortical carcinomas.
Sarkaria IS; Stojadinovic A; Talbot SG; Hoos A; Dudas ME; Brennan MF; Ghossein RA; Singh B
Surgery; 2004 Dec; 136(6):1122-8. PubMed ID: 15657565
[TBL] [Abstract][Full Text] [Related]
23. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.
Xu F; Guan Y; Zhang P; Xue L; Ma Y; Gao M; Chong T; Ren BC
BMC Endocr Disord; 2022 May; 22(1):130. PubMed ID: 35568842
[TBL] [Abstract][Full Text] [Related]
24. De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry.
Balluff B; Frese CK; Maier SK; Schöne C; Kuster B; Schmitt M; Aubele M; Höfler H; Deelder AM; Heck A; Hogendoorn PC; Morreau J; Maarten Altelaar AF; Walch A; McDonnell LA
J Pathol; 2015 Jan; 235(1):3-13. PubMed ID: 25201776
[TBL] [Abstract][Full Text] [Related]
25. Identification of NDRG Family Member 4 (NDRG4) and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) as Key Prognostic Genes in Adrenocortical Carcinoma by Transcriptomic Analysis.
Yang Z; Cheng H; Zhang Y; Zhou Y
Med Sci Monit; 2021 Mar; 27():e928523. PubMed ID: 33667214
[TBL] [Abstract][Full Text] [Related]
26. Identification of important invasion and proliferation related genes in adrenocortical carcinoma.
Alshabi AM; Vastrad B; Shaikh IA; Vastrad C
Med Oncol; 2019 Jul; 36(9):73. PubMed ID: 31321566
[TBL] [Abstract][Full Text] [Related]
27. IL-13Rα2 gene expression is a biomarker of adverse outcome in patients with adrenocortical carcinoma.
Kumar A; Bellayr IH; Singh HS; Puri RK
PLoS One; 2021; 16(2):e0246632. PubMed ID: 33591997
[TBL] [Abstract][Full Text] [Related]
28. Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment.
Bussey KJ; Demeure MJ
Future Oncol; 2009 Jun; 5(5):641-55. PubMed ID: 19519204
[TBL] [Abstract][Full Text] [Related]
29. Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma.
Fu Y; Sun S; Bi J; Kong C; Yin L
Medicine (Baltimore); 2021 Mar; 100(10):e25031. PubMed ID: 33725886
[TBL] [Abstract][Full Text] [Related]
30. Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma.
Gao Z; Man X; Li Z; Bi J; Liu X; Li Z; Zhu Y; Zhang Z; Kong C
Oncol Rep; 2019 Apr; 41(4):2440-2452. PubMed ID: 30816525
[TBL] [Abstract][Full Text] [Related]
31. Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.
Xu C; Qin C; Jian J; Peng Y; Wang X; Chen X; Wu D; Song Y
Immun Inflamm Dis; 2022 Sep; 10(9):e680. PubMed ID: 36039643
[TBL] [Abstract][Full Text] [Related]
32. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods.
Li X; Gao Y; Xu Z; Zhang Z; Zheng Y; Qi F
Cancer Med; 2020 Feb; 9(3):1161-1172. PubMed ID: 31856409
[TBL] [Abstract][Full Text] [Related]
33. Prognosis and Therapeutic Efficacy Prediction of Adrenocortical Carcinoma Based on a Necroptosis-Associated Gene Signature.
Ji D; Zhong R; Fan S
Biomed Res Int; 2022; 2022():8740408. PubMed ID: 35647181
[TBL] [Abstract][Full Text] [Related]
34. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
35. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.
Arlt W; Biehl M; Taylor AE; Hahner S; Libé R; Hughes BA; Schneider P; Smith DJ; Stiekema H; Krone N; Porfiri E; Opocher G; Bertherat J; Mantero F; Allolio B; Terzolo M; Nightingale P; Shackleton CH; Bertagna X; Fassnacht M; Stewart PM
J Clin Endocrinol Metab; 2011 Dec; 96(12):3775-84. PubMed ID: 21917861
[TBL] [Abstract][Full Text] [Related]
36. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.
Sbiera I; Kircher S; Altieri B; Lenz K; Hantel C; Fassnacht M; Sbiera S; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():795116. PubMed ID: 34956100
[TBL] [Abstract][Full Text] [Related]
37. Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real-world data.
Tian X; Xu W; Wang Y; Anwaier A; Wang H; Wan F; Zhu Y; Cao D; Shi G; Zhu Y; Qu Y; Zhang H; Ye D
Oncoimmunology; 2020 Jun; 9(1):1784529. PubMed ID: 32923148
[TBL] [Abstract][Full Text] [Related]
38. Adrenocortical carcinoma - towards genomics guided clinical care.
Crona J; Beuschlein F
Nat Rev Endocrinol; 2019 Sep; 15(9):548-560. PubMed ID: 31147626
[TBL] [Abstract][Full Text] [Related]
39. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
40. System analysis identifies UBE2C as a novel oncogene target for adrenocortical carcinoma.
Huang R; Guo L; Chen C; Xiang Y; Li G; Zheng J; Wu Y; Yuan X; Zhou J; Gao W; Xiang S
PLoS One; 2023; 18(8):e0289418. PubMed ID: 37535572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
